contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


xintela-ab-interim-report-january-june-2024

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Xintela är verksamt inom bioteknik. Bolagets kompetens återfinns inom regenerativ medicin, samt behandling av cancer, ledbroskskador samt hjärntumörer. Forskningen baseras på utvecklandet av proteinmolekyler som har kapacitet att känna av förändringar på cellers yta, vilket möjliggör identifiering av de stamceller som är på väg att utvecklas till broskceller. Bolaget grundades under 2009 och har sitt huvudkontor i Lund.

Xintela

Summary of the interim report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.THE GROUP Second quarter 2024 Income amounted to TSEK 4 (0). Loss...

<div class="mfn-body">Summary of the interim report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.THE GROUP Second quarter 2024 Income amounted to TSEK 4 (0). Loss before tax totalled TSEK 10,400 (loss: 18,401). Loss per share was SEK 0.02 (loss: 0.06). &nbsp; First half year 2024 Income amounted to TSEK 303 (0). Loss before tax totalled TSEK 21,773 (loss: 34,244). Loss per share was SEK 0.04 (loss: 0.11). &nbsp; THE PARENT COMPANY Second quarter 2024 Income amounted to TSEK 4 (0). Loss before tax totalled TSEK 8,565 (loss: 11,151). Loss per share was SEK 0.02 (loss: 0.04). &nbsp; First half year 2024 Income amounted to TSEK 303 (0). Loss before tax totalled TSEK 18,254 (loss: 21,553). Loss per share was SEK 0.03 (loss: 0.07). At June 30, 2024, the equity/assets ratio was 44 % (17). &nbsp; Significant events in the second quarter of 2024 Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses. (May 23, 2024)Significant events after the end of the period Xintela extends clinical study with XSTEM on knee osteoarthritis patients. (August 23, 2024) Xintela signs agreement with Region Östergötland for GMP process development of cell therapy for burn patients. (August 29, 2024) &nbsp; The complete report is available for download below and on the company’s website&nbsp;<a rel="noopener" href="http://www.xintela.se/en/report-archive">www.xintela.se/en/report-archive.</a> &nbsp;</div><div class="mfn-footer mfn-contacts mfn-09e6822ea9f2">Contacts<hr>Xintela AB (publ) Evy Lundgren-Åkerlund, CEO Tel: +46 46 275 65 00 Email: <a rel="noopener" href="mailto:evy@xintela.se">evy@xintela.se</a> Medicon Village 223 81 Lund, Sweden <a rel="noopener" href="http://www.xintela.se">www.xintela.se</a></div><div class="mfn-footer mfn-about mfn-db06a6a75d7d">About Xintela<hr>Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser is Carnegie Investment Bank AB (publ).</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/a8b606ac-ae91-4105-82f6-9893d379a56e/xintela-2024-q2-en.pdf" class="mfn-primary">Xintela 2024 Q2 EN</a></div>

Beställ vårt nyhetsbrev — inget användarkonto krävs!